Industry Educational Session - Start Strong in 1L CLL and MCL: New Licenses, Data Updates & Complex Cases - Sponsored by AstraZeneca
Tracks
-
| Monday, April 20, 2026 |
| 2:30 PM - 3:15 PM |
| Hall 3A, Upper Level |
Details
• 1L CLL Updates: Evaluating fixed-duration and continuous treatment options in current practice
• Advancements in MCL: Discussion of BTKi treatment options for eligible 1L patients
• Clinical Application: Leveraging real-world evidence and case studies to optimise patient outcomes
This is a promotional symposium created and funded by AstraZeneca and intended for UK healthcare professionals only.
GB-74550
Date of preparation: March 2026
Speaker
Dr Toby Eyre
Consultant Haematologist
Oxford University Hospitals NHS Foundation Trust
Speaker One
Dr Eyre is a consultant haematologist specialising in lymphoid malignancies in Oxford, UK. He has completed an MD Doctorate Thesis in 2017. He is an investigator on several national lymphoid trials and has published over 175 peer-review articles on lymphoma and CLL. He is the low-grade lymphoma clinical trial research group chair in the UK. He is a core member of several lymphoma studies groups. He is a member of the BSH guideline writing groups for various lymphoma subtypes. He is an Associate Editor at the British Journal of Haematology. He is the lead author for the new ESMO Lymphoma guidelines.
Dr David Dutton
Consultant Haematologists
University Hospital Southampton
Speaker Two
Dr Dutton is a Consultant Haematologist and honorary clinical senior lecturer working in the CLL and lymphoma team at the University Hospitals Southampton (UHS) and University of Southampton. David is a member of the UK chronic lymphocytic leukaemia forum, with a focus on the biology and treatment of chronic B cell lymphoproliferative disorders.
Stella Williams
Clatterbridge Cancer Centre
Speaker Three
Dr Stella Williams is a consultant haematologist at the Clatterbridge Cancer Centre, Liverpool, specialising in lymphoma and CLL. She is on the executive committee for the UK CLL Forum, a member of the NCRI CLL study group, and actively participates in clinical research at Clatterbridge.
